Factores de crecimiento y angiogénesis en prolactinomas resistentes a dopamina

CAROLINA CRISTINA; ISABEL GARCÍA TORNADÚ; M INÉS PÉREZ MILLÁN; GRACIELA DÍAZ-TORGA; DAMASIA BECÚ-VILLALOBOS

Anales de la Academia Nacional de Ciencias (Buenos Aires)

Editorial Ronaldo J Pellegrini Impresiones

Lugar: Buenos Aires; Año: 2006; p. 1 - 15

Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GHIGF axis. In D2R KO, lactotropes do not show dense secretory granules but degranulated cells, and fewer somatotropes, gonadotropes and thyrotropes. Prolactin levels are always higher in female than in male knockouts, and in accordance, pituitary hyperplasia is observed at 8 months only in females.After 16 months of age highly vascularized adenomas develop, especially in females, but also in males. Prominent vascular channels in the hyperplastic and adenomatous pituitaries, as well as extravasated red blood cells not contained in capillaries is also a common finding.VEGF-A expression is increased in pituitaries from D2R KO. VEGFA is expressed in folliclestellate cells. Because D2R receptors are found in lactotropes and not in folliclestellate cells it may be inferred that paracrine-derived factor from lactotropes is acting on folliclestellate cells to increase VEGF-A expression. VEGF-A does not induce pituitary cell proliferation, even though it enhances prolactin secretion. But it may act on adjacent endothelial cells and participate in the angiogenic process that increases the availability of different growth factors and mitogens. We postulate that the D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology.